These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26775546)

  • 21. Impact of pharmacotherapy on interstage outcomes in single ventricle infants.
    Moffett BS; Mattamal R; Ocampo EC; Petit CJ
    Congenit Heart Dis; 2011; 6(4):286-93. PubMed ID: 21696551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Australia and New Zealand Fontan Registry: description and initial results from the first population-based Fontan registry.
    Iyengar AJ; Winlaw DS; Galati JC; Gentles TL; Weintraub RG; Justo RN; Wheaton GR; Bullock A; Celermajer DS; d'Udekem Y
    Intern Med J; 2014 Feb; 44(2):148-55. PubMed ID: 24393144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations].
    de Leeuw PW
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1605-7. PubMed ID: 16901062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letter by Burchill et al regarding article, "Enalapril in infants with single ventricle: results of a multicenter randomized trial".
    Burchill LJ; Ross HJ; Wald RM
    Circulation; 2011 Mar; 123(10):e373. PubMed ID: 21403119
    [No Abstract]   [Full Text] [Related]  

  • 25. [Angiotensin-converting enzyme inhibitors. Familiar drugs--new indications].
    Gregor P
    Cas Lek Cesk; 1998 Mar; 137(5):150-3. PubMed ID: 9588098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ; Bailey EK; Reed AN; Gales MA
    Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of patients born with single-ventricle physiology and aortic arch obstruction: the 26-year Melbourne experience.
    Lee MG; Brizard CP; Galati JC; Iyengar AJ; Rakhra SS; Konstantinov IE; Pflaumer A; d'Udekem Y
    J Thorac Cardiovasc Surg; 2014 Jul; 148(1):194-201. PubMed ID: 24075567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.
    López-Sendón J; Swedberg K; McMurray J; Tamargo J; Maggioni AP; Dargie H; Tendera M; Waagstein F; Kjekshus J; Lechat P; Torp-Pedersen C;
    Eur Heart J; 2004 Aug; 25(16):1454-70. PubMed ID: 15302105
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-versus low-dose ACE inhibitor therapy in chronic heart failure.
    Roffman DS
    Ann Pharmacother; 2004 May; 38(5):831-8. PubMed ID: 15026561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE inhibition in the 1990s.
    Maxwell SR; Kendall MJ
    Br J Clin Pract; 1993; 47(1):30-7. PubMed ID: 8461246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early or late ACE inhibition after myocardial infarction.
    Ball SG
    J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S18-21. PubMed ID: 7514236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Malde B; Regalado J; Greenberger PA
    Ann Allergy Asthma Immunol; 2007 Jan; 98(1):57-63. PubMed ID: 17225721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ACE inhibitors continue to be first choice in the treatment of heart failure patients].
    Gadsbøll N; Pedersen CT
    Ugeskr Laeger; 2013 May; 175(22):1566-8. PubMed ID: 23721841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases.
    Liao Y; Husain A
    Can J Cardiol; 1995 Aug; 11 Suppl F():13F-19F. PubMed ID: 7664213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should you take an ACE inhibitor?
    Johns Hopkins Med Lett Health After 50; 2000 Mar; 12(1):1-2. PubMed ID: 10740441
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.
    Cooper WO
    J Cardiovasc Nurs; 2008; 23(1):20-4. PubMed ID: 18158502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.